M&A in 2026: Auditing the Algorithm in Life Sciences Acquisitions
Private equity firms are aggressively shifting capital from traditional drug pipelines to AI-driven discovery platforms. However, standard M&A due diligence is entirely unequipped to evaluate a target company's AI architecture. If a PE firm acquires a life sciences platform without forensically auditing its data governance, algorithmic bias, and 21 CFR Part 11 compliance, they are buying a massive federal liability, not an operational asset.
Margin Impact
Acquiring unvalidated AI architecture creates a scenario where the buyer absorbs the cost of total system reconstruction. Identifying these algorithmic flaws pre-close allows M&A directors to aggressively drive down target valuations and structure deals with heavy escrow holdbacks.
Tactical Execution
Audit the Training Data: Do not just evaluate the software; audit the origin, compliance, and patient privacy parameters of the data used to train the target company's AI models.
Stress-Test 21 CFR Part 11: Ensure the target's digital ecosystem has immutable audit trails and e-signature compliance baked into its source code.
Quantify Algorithmic Debt: Calculate the CapEx required to bring the target's AI systems up to aerospace-grade validation standards and subtract it directly from the purchase price.